Kristin Yarema, PhD

Kristin Yarema, Ph.D. brings over two decades of leadership experience in therapeutics to Imagene. Her most recent role as Chief Executive Officer and Director of Poseida Therapeutics (formerly Nasdaq: PSTX) culminated in an acquisition by Roche in January 2025, after which she stayed to guide the transition. She previously held the position of President, Cell Therapy at Poseida from April 2023 to December 2023. Prior to Poseida, Dr. Yarema served as Chief Commercial Officer at Atara Biotherapeutics (Nasdaq: ATRA), from February 2020 to November 2022. She also held numerous senior positions at Amgen, including Vice President and Therapeutic Area Head roles in inflammation (autoimmune), bone, nephrology, hematology, cardiovascular, metabolism, and neuroscience, as well as commercial leadership in dermatology and rheumatology. Earlier in her career, Dr. Yarema held various senior clinical development, portfolio, and global commercial leadership roles at Novartis, and was an Associate Principal in McKinsey & Company’s healthcare practice. Dr. Yarema currently serves on the boards of directors of the Celiac Disease Foundation and the Alliance for Regenerative Medicine. She holds a B.S. in Chemical Engineering and B.A. in English from Stanford University, and a Ph.D. in Chemical Engineering from the University of California, Berkeley.